Diebold Nixdorf Cuts 2026 Outlook Despite 5% Q3 Revenue Growth; Authorizes New $250M Buyback
DBD sits 24% above its 52-week low of $54.48.
Summary
Diebold Nixdorf grew Q3 revenue 5% to $994.3M but cut full-year adjusted EBITDA and free cash flow guidance, while authorizing a new $250M share repurchase program.
Key Events · Earnings and Guidance · DBD
-
Q3 Revenue Up 5% to $994.3M
Revenue rose 5.2% from $945.2M, led by Retail growth; adjusted EBITDA increased to $127.8M from $121.9M.
-
Full-Year Guidance Cut
Adjusted EBITDA guidance was lowered to $490M-$510M from $510M-$535M, free cash flow to $190M-$210M from $255M-$270M, and adjusted EPS to $4.50-$4.85 from $5.25-$5.75, citing product mix and raw-material costs.
-
Q3 Cash Flow Negative
Net cash used in operations was $(47.4)M and free cash flow use was $(45.9)M excluding discrete tax payments, driven by VAT refund timing and working capital.
-
New $250M Buyback Authorized
The board authorized a new $250M share repurchase program, following $115M repurchased in H1 2026.
Analysis · DBD · Technology
The headline growth masks a tougher cash story. Revenue rose 5% to $994.3M and adjusted EBITDA climbed to $127.8M, yet management cut full-year adjusted EBITDA guidance to $490M-$510M from $510M-$535M and free cash flow to $190M-$210M from $255M-$270M, pointing to product mix and raw-material cost pressure. The free-cash-flow reduction is the sharpest item: Q3 free cash flow was a $(45.9)M use excluding discrete tax payments, and the company now pays German cash tax across three tax years, with roughly $50M of 2024/2025 German tax excluded from the FCF definition. A new $250M buyback authorization offsets some of the negative read, but the lowered cash outlook is what changes the near-term thesis.
How filings like this one have moved
In the 30 days to Oct 28, 2026, 36.5% of the 953 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.66%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DBD was trading at $67.49 on NYSE in the Technology sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $54.48 to $92.09. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.